{"id":"NCT01365481","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age","officialTitle":"A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2011-06-03","resultsPosted":"2016-04-21","lastUpdate":"2016-07-13"},"enrollment":150,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension","Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Valsartan","otherNames":["VAL489"]},{"type":"DRUG","name":"amlodipine","otherNames":[]},{"type":"DRUG","name":"Hydrochlorothiazide","otherNames":["HCTZ"]}],"arms":[{"label":"valsartan","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety and tolerability profile of valsartan and valsartan-based treatments in children with hypertension, with or without chronic kidney disease.","primaryOutcome":{"measure":"Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)","timeFrame":"Baseline, End Point (Week 78 or Last observation carried forward (LOCF)","effectByArm":[{"arm":"Valsartan + Antihypertensive Group","deltaMin":-13.3,"sd":13.69},{"arm":"Valsartan Alone","deltaMin":-15.5,"sd":13.35}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":28,"countries":["Colombia","Finland","Germany","Guatemala","Philippines","Poland","Romania","Russia","Singapore","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":41},"commonTop":["Headache","Cough","Nasopharyngitis","Pyrexia","Dizziness"]}}